Clinical and economic evaluation of exenatide for formulary decisions

Journal of Medical Economics

Volumn 10, Issue 4, 2007, Pages 529-537

  Shaya, Fadia T ^a   Sohn, Kyongsei ^a   Lee, Samuel ^a   Bleu Laine, Raymond ^a   Lim, Jeanne ^a   Casciano, Matthew ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Budget impact analysis; Cost effectiveness; Diabetes; Exenatide; Formulary; Managed care

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C;

ARTICLE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG RESEARCH; ECONOMIC EVALUATION; HEALTH CARE ORGANIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SENSITIVITY ANALYSIS; TREATMENT FAILURE;

EID: 38148998716     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701748415     Document Type: Article

References (18)

1. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Diabetes in America, 2nd edn. Bethesda, MD: National Diabetes Information Clearinghouse: 47-68. Available at: http://diabetes.niddk.nih.gov/dm/pubs/america/contents.htm [accessed 11 October 2007].
2. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Diabetes Statistics. Available at: http://diabetes.niddk.nih. gov/dm/pubs/statistics/index.htm [accessed 11 October 2007].
3. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Fact Sheet. Available at: http://www.cdc.gov/diabetes/pubs/ factsheet05.htm [accessed 11 October 2007].
4. Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20 (Suppl 1): S5-S26.
5. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. Journal of Clinical Endocrinology and Metabolism 1994; 78: 809A-809F.
6. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30 (Suppl 1): S4-S41.
7. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine 2003; 163: 1306-1316.
8. American Diabetes Association. Available at: http://www.diabetes.org/ home.jsp [accessed 11 October 2007].
9. Byetta® [prescribing information]. Amylin Pharmaceuticals, 2007. Available at: http://pi.lilly.com/us/byetta-pi.pdf [accessed 11 October 2007].
10. Buse JB, Henry RB, Han J et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
11. Defronzo RA, Ratner RE, Han J et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
12. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
13. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London, UK: Chapman & Hall, 1993.
14. Managed Care Dossier. BYETTA® (exenatide). Indianapolis, IN: Eli Lilly, 2005.
15. Gold MR, Siegel JE, Russell LB et al. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press, 1996.
16. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218-1224.
17. Siminerio L. Challenges and strategies for moving patients to injectable medications. The Diabetes Educator 2006; 32 (Suppl 2): S82-S90.
18. Secnik Boye K, Matza LS, Oglesby A et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes 2006; 4: 80.